Global Esophageal Cancer Market - 2021-2028
The global esophageal cancer market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Esophageal cancer is a condition in which cancer cells form in the tissues of the esophagus. Smoking, excess alcohol, and Barrett's esophagus can raise the risk of esophageal cancer. Signs and indications of esophageal cancer are weight loss and pain or trouble in swallowing. This cancer starts on the interior lining of the esophagus and flows outward within the other layers as it progresses. At succeeding stages, esophageal cancer can be treated but infrequently can be cured.
The esophageal cancer market growth is driven by the the rise in cases of esophageal cancer which creates an opportunity for the pharma companies to introduce novel therapy and promising pipeline drugs. In addition, advances in the treatment rate and adoption of sedentary life-style are some of the impacting factors for the demand of esophageal cancer drugs.
Increasing research and development for the treatment of esophageal cancer will drive the market growth
Rising research and development and launches of novel products by key players are significant constituents is expected to drive the growth of the global esophageal cancer market in the forecast period. Increasing research and development for new drug discovery for the treatment of esophageal cancer is expected to drive the growth of esophageal cancer drug market size significantly.
For instance, in February 2019, researchers at Case Western Reserve University discovered that blocking two molecular pathways that send signals inside cancer cells could reduce esophageal adenocarcinoma, the most common esophageal malignancy the U.S. These findings suggest JNK/TGF-beta-targeted therapy as a new treatment approach to treat esophageal cancer.
Government of several economies and various non-government organizations are taking initiatives to increase patient awareness about esophageal cancer. Research related to esophageal cancer has recently caught the consideration of oncologists and experts. The enormous scale of disease types associated with esophageal cancer is behind the revitalized interest of the medical fraternity. Moreover, increased consumption of carcinogens existing in specific foods has also become a concern for oncologists. Therefore, the growth of the global esophageal cancer market mainly hinges on the efforts taken by the medical organization to alleviate the occurrence of esophageal cancer.
The prevalence of achalasia is expected to drive the esophageal cancer market growth
The significant risk factors that lead to esophageal cancer include age, gender, tobacco, alcohol, Barrett's esophagus, obesity, and achalasia. These factors will increase the demand for esophageal cancer drugs over the forecast period. For instance, according to a study published in National Center for Biotechnology Information in 2017, achalasia patients have a 50 times more prominent risk of esophageal squamous cell carcinoma than the general population. The overall predominance of achalasia is 9 to 10 in 100,000 people annually worldwide.
The rising prevalence of disorders like adenocarcinoma and squamous cell carcinoma in the US also contributes to the market's growth in the forecast period. In addition, the consecutive occurrence of GERD causes dysplasia, eventually resulting in uncontrolled growth of cells in the esophagus. This factor will further increase the esophageal cancer market in the forecast period.
Side effects associated with certain medications coupled with high cost of cancer treatment
The side effects begun by esophageal cancer drugs are loss of hunger and weight loss, weakness, diarrhea, sore mouth, hair loss, low blood cell counts, hand-foot syndrome, blood clots (deep vein thrombosis), heart damage and nervous system damage. According to the report published in the American Cancer Society (ACS) in 2017, the side effects of esophageal cancer drugs such as Cisplatin, oxaliplatin, docetaxel, and paclitaxel can cause significant damage to nerves outside the brain and spinal cord.
The high cost of the therapy in the treatment of esophageal cancer will hamper the market growth in the forecast period. For instance, according to the report published by HealthDay, cancer patients paid US$ 207,000 per year for their treatment and medicines, while in 1995, the cost was US$ 54,100 per year.
Reports suggest a higher risk of COVID-19 infection with associated severe morbidity and mortality in cancer patients. The complexity of the multidisciplinary approach to esophageal cancer patients and the high morbidity rates of esophageal surgery has challenged the treatment pathways of these patients.
According to Oxford Academics, the surgery of patients who have cancer was limited in 24 (36.9%) patients in 6 (50%) centers, mostly due to deficiency of anesthesiologists and occupation of intensive care unit beds from intubated COVID-19 patients. Implications for neoadjuvant chemo (radio) therapy were increased in 14% of patients. Separate COVID-19 hospital pathways were active in 11 (91.7%) units. COVID-19 screening protocols covered nasopharyngeal swab in 91.7%, chest computed tomography scan in 8.3% and particular use of lung ultrasound in 75% of units. Postoperative interstitial pneumonia occurred in 1 (1.5%) patient.
Gastrointestinal stromal tumors segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Gastrointestinal stromal tumors (GISTs) are unusual cancers that arise in specific cells on the surface of the gastrointestinal (GI) tract, and it is also known as the digestive tract. The GI tract prepares food for energy and rids the body of fixed waste.
The food and gastric juices are then discharged into the small intestine. The small intestine continues busting down the food and absorbs most of the nutrients into the bloodstream. Some GISTs seem to be much more likely than others to grow into other areas or spread to other parts of the body.
GISTs Cancers can occur anywhere in the GI tract, from the throat to the anus. Most cancers that start in the GI tract, including most esophagus cancers, stomach cancers, and colon and rectum cancers, start in the gland cells that line almost all GI tracts. The malignancies that develop in these cells are called adenocarcinomas.
The GI tract also has neuroendocrine cells. These cells have some features in common with nerve cells but also have other features in common with hormone-producing (endocrine) cells. Cancers that develop from these cells are called neuroendocrine tumors (NETs). These cancers are rare in the GI tract. Carcinoid tumors are an example of a neuroendocrine tumor found in the GI tract.
The chemotherapy segment are expected to dominate the esophageal cancer market during the forecast period
Chemotherapy is the use of anti-cancer medications used to treatment of cancerous cells. Chemotherapy has been done for many years and is one of the most prevalent cancer treatments. In most instances, chemotherapy works by preventing the cancer cell's ability to grow or multiply. Several groups of medications work in many ways to fight cancer cells. Chemotherapy may be used alone for some types of cancer or in sequence with other treatments such as radiation or surgery. Often, a mixture of chemotherapy drugs is used to fight particular cancer. Some chemotherapy drugs are given in a specific amount depending on the type of cancer used for treatment.
While chemotherapy can be quite efficient in treating specific cancers, chemotherapy medications reach all body parts. The carcinoma cells that cause may be many side effects during therapy.
North America region holds the largest market share global Esophageal Cancer Market
North America region is dominating the esophageal cancer market accounted for the largest market share in 2020, owing to the growing prevalence of esophageal cancer in this region. For instance, the according to American Cancer Society's report, it projected that around 17,650 new esophageal cancer cases will be diagnosed (13,750 in men and 3,900 in women) in the U.S. by 2019.
Numerous cancer research institutes and Universities have linked their synergies to develop a stable method for treating melanoma. Case Western Reserve University in the United States, in the initial quarter of 2019, developed a pathway that can restrain the occurrence of esophageal cancer. The research was based on testimony collected from an extended series of examinations. Such advancements are expected to develop the possibilities of growth in the esophageal cancer market in the region.
The esophageal cancer market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., Eli Lilly and Company, Hoffmann-La Roche, Bristol-Myers Squibb Company, and Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Sanofi-Aventis Merck & Co. Among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the esophageal cancer market globally.
Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.
Product Portfolio: The Company's portfolio comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology and neuroscience areas.
The global esophageal cancer market report would provide an access to an approximately 45+ market data table, 40+ figures and 180 pages.
Global Esophageal Cancer Market - By Type
Global Esophageal Cancer Market- By Therapy
Global Esophageal Cancer Market - By End User
Global Esophageal Cancer Market - By Region
LIST NOT EXHAUSTIVE